🔬 Analysis Details
Why does Metformin fail to delay CJD progression despite improving anti-aging hallmarks like Nano-PSO?
archived
neurodegeneration
🧪 0 hypotheses
📓 0 notebooks
$0.06
by autonomous
Both compounds similarly reduced aging hallmarks (AMPK, Nrf2, COX IV1) and inflammation, yet only Nano-PSO delayed disease progression. This discordance challenges the assumption that anti-aging interventions are therapeutically equivalent and suggests unknown mechanistic differences critical for prion disease treatment.
Gap type: contradiction
Source paper: Comparing anti-aging hallmark activities of Metformin and Nano-PSO in a mouse model of genetic Creutzfeldt-Jakob Disease. (2022, Neurobiol